EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis

Qingtao Liu, Pei Xu, Mingming Jin, Lei Wang, Fengqing Hu, Qi Yang, Rui Bi, Haibo Xiao, Lianyong Jiang, Fangbao Ding

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03634-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Qingtao Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, School of Medicine, Xinhua Hospital Affiliated Shanghai Jiao Tong University, Shanghai, 200092, People's Republ…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Extracellular Vesicles, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Accumulation studies found that tumor-associated macrophages (TAMs) are a predominant cell in tumor microenvironment (TME), which function essentially during tumor progression. By releasing bioactive molecules, including circRNA, small extracellular vesicles (sEV) modulate immune cell functions in the TME, thereby affecting non-small cell lung cancer (NSCLC) progression. Nevertheless, biology functions and molecular mechanisms of M2 macrophage-derived sEV circRNAs in NSCLC are unclear.

Methods

Cellular experiments were conducted to verify the M2 macrophage-derived sEV (M2-EV) roles in NSCLC. Differential circRNA expression in M0 and M2-EV was validated by RNA sequencing. circFTO expression in NSCLC patients and cells was investigated via real-time PCR and FISH. The biological mechanism of circFTO in NSCLC was validated by experiments. Our team isolated sEV from M2 macrophages (M2Ms) and found that M2-EV treatment promoted NSCLC CP, migration, and glycolysis.

Results

High-throughput sequencing found that circFTO was highly enriched in M2-EV. FISH and RT-qPCR confirmed that circFTO expression incremented in NSCLC tissues and cell lines. Clinical studies confirmed that high circFTO expression correlated negatively with NSCLC patient survival. Luciferase reporter analysis confirmed that miR-148a-3p and PDK4 were downstream targets of circFTO. circFTO knockdown inhibited NSCLC cell growth and metastasis in in vivo experiments. Downregulating miR-148a-3p or overexpressing PDK4 restored the malignancy of NSCLC, including proliferation, migration, and aerobic glycolysis after circFTO silencing.

Conclusion

The study found that circFTO from M2-EV promoted NSCLC cell progression and glycolysis through miR-148a-3p/PDK4 axis. circFTO is a promising prognostic and diagnostic NSCLC biomarker and has the potential to be a candidate NSCLC therapy target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungExtracellular VesiclesLung NeoplasmsMicroRNAsHumansCell Line, TumorCell ProliferationMacrophagesRNA, CircularTumor MicroenvironmentAlpha-Ketoglutarate-Dependent Dioxygenase FTOPyruvate Dehydrogenase Acetyl-Transferring Kinase

Stichwörter der Autor:innen

NSCLCPDK4Small extracellular vesicles (sEV)circFTOmiR-148a-3p

Substanzen

MicroRNAsRNA, CircularFTO protein, humanAlpha-Ketoglutarate-Dependent Dioxygenase FTOMIRN148 microRNA, humanPDK4 protein, humanPyruvate Dehydrogenase Acetyl-Transferring Kinase

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, School of Medicine, Xinhua Hospital Affiliated Shanghai Jiao Tong University, Shanghai, 200092, People's Republic of China.
  • Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, People's Republic of China.
  • Department of Cardiothoracic Surgery, School of Medicine, Xinhua Hospital Affiliated Shanghai Jiao Tong University, Shanghai, 200092, People's Republic of China. xiaohaibo@xinhuamed.com.cn.
  • Department of Cardiothoracic Surgery, School of Medicine, Xinhua Hospital Affiliated Shanghai Jiao Tong University, Shanghai, 200092, People's Republic of China. jianglianyong@xinhuamed.com.cn.
  • Department of Cardiothoracic Surgery, School of Medicine, Xinhua Hospital Affiliated Shanghai Jiao Tong University, Shanghai, 200092, People's Republic of China. dingfangbao@xinhuamed.com.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Q., Xu, P., Jin, M., Wang, L., Hu, F., Yang, Q., Bi, R., Xiao, H., Jiang, L., & Ding, F. (2024). circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03634-4

Vancouver

Liu Q, Xu P, Jin M, Wang L, Hu F, Yang Q, et al. circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03634-4

BibTeX
@article{Liu2024,
  author = {Liu, Qingtao and Xu, Pei and Jin, Mingming and Wang, Lei and Hu, Fengqing and Yang, Qi and Bi, Rui and Xiao, Haibo and Jiang, Lianyong and Ding, Fangbao},
  title = {circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03634-4}
}
Kostenlos starten →